Low-dose radiation plus chemo and immunotherapy for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread, and you have already tried one standard treatment that didn't work.
- You are in generally good health for your age, with a performance status of 0 to 2 (meaning you can care for yourself or are up and about more than half the day).
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver, kidney, and heart function are within certain limits as checked by blood tests.
- You are willing to use effective contraception during treatment and for 120 to 180 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
This trial tests a new sequence of treatments for advanced stomach cancer that has spread to the lining of the abdomen. You would first get low-dose radiation, then a combination of immunotherapy, chemotherapy, and a special type of chemotherapy delivered directly into the belly, to see if it can control the cancer and improve quality of life.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.